Daniel P. Petrylak, MD, presented “Overview – Bladder Cancer Clinical Trials Where We Stand At The End Of 2024” at the 7th International Bladder Cancer Update on December 6, 2024, in Dallas, Texas.
How to cite: Petrylak, Daniel P. “Overview – Bladder Cancer Clinical Trials Where We Stand At The End Of 2024” December 2024. Accessed Feb 2025. https://grandroundsinurology.com/overview-bladder-cancer-clinical-trials-where-we-stand-at-the-end-of-2024/
Overview – Bladder Cancer Clinical Trials Where We Stand At The End Of 2024 – Summary
Daniel P. Petrylak, MD, delivers an in-depth analysis of bladder cancer treatment advancements, emphasizing recent clinical practice breakthroughs and challenges.
In this 23-minute presentation, Dr. Petrylak shares that bladder cancer remains one of the most common urinary malignancies. The field has seen major progress in the last decade, shifting from limited treatment options to a range of novel therapies, including immune checkpoint inhibitors, antibody-drug conjugates, and targeted agents.
Dr. Petrylak highlights recent FDA approvals, such as enfortumab vedotin, erdafitinib, and nivolumab in combination therapies, reshaping first- and second-line treatment strategies. Clinical trials are exploring sequencing and combination approaches with new immunotherapies and drug-delivery technologies.
Challenges in toxicity management, particularly neuropathy with enfortumab vedotin, are highlighted as a key concern, requiring careful monitoring. Petrylak notes emerging research focuses on molecular subtyping, targeting FGFR and HER2 alterations to optimize personalized treatment. Neoadjuvant and adjuvant therapy strategies are evolving, with trials like KEYNOTE-095 and VOLGA evaluating immunotherapy before surgery.
Dr. Petrylak stresses that the future of bladder cancer treatment lies in refining therapeutic sequences, minimizing toxicity, and integrating new agents to improve survival and long-term outcomes.
About the 7th International Bladder Cancer Update:
The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Daniel P. Petrylak, MD, leads the genitourinary cancers medical oncology team at Smilow Cancer Hospital as director of the genitourinary cancer research group, professor, and co-director of the Cancer Signaling Network program. Dr. Petrylak joined Yale from Herbert Irving Cancer Center at Columbia University Medical Center with New York-Presbyterian Hospital, where he served as Professor of Medicine (Medical Oncology) and Urology and began his appointment in September of 2012. After serving for more than 20 years as the advanced bladder chair for SWOG, Dr. Petrylak is now the Vice Chair of the Genitourinary Committee.
